These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 9817388)

  • 21. [Benign prostatic hyperplasia and growth factors: mechanisms and hypotheses].
    Aumüller G
    Urologe A; 1992 May; 31(3):159-65. PubMed ID: 1377433
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of canine basal cells in postnatal prostatic development, induction of hyperplasia, and sex hormone-stimulated growth; and the ductal origin of carcinoma.
    Leav I; Schelling KH; Adams JY; Merk FB; Alroy J
    Prostate; 2001 Aug; 48(3):210-24. PubMed ID: 11494337
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Benign prostatic hyperplasia: a review of its histogenesis and natural history.
    Oesterling JE
    Prostate Suppl; 1996; 6():67-73. PubMed ID: 8630233
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Testicular steroids, prolactin, relaxin and prostate gland markers in peripheral blood and seminal plasma of normal dogs and dogs with prostatic hyperplasia.
    Wolf K; Kayacelebi H; Urhausen C; Piechotta M; Mischke R; Kramer S; Einspanier A; Oei CH; Günzel-Apel A
    Reprod Domest Anim; 2012 Dec; 47 Suppl 6():243-6. PubMed ID: 23279510
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of combination treatment with zanoterone (WIN 49596), a steroidal androgen receptor antagonist, and finasteride (MK-906), a steroidal 5 alpha-reductase inhibitor, on the prostate and testes of beagle dogs.
    Juniewicz PE; Hoekstra SJ; Lemp BM; Barbolt TA; Devin JA; Gauthier E; Frenette G; Dube JY; Tremblay RR
    Endocrinology; 1993 Aug; 133(2):904-13. PubMed ID: 8393778
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interleukin-1alpha is a paracrine inducer of FGF7, a key epithelial growth factor in benign prostatic hyperplasia.
    Giri D; Ittmann M
    Am J Pathol; 2000 Jul; 157(1):249-55. PubMed ID: 10880394
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunohistochemical localization of the androgen receptor in rat and human tissues.
    Sar M; Lubahn DB; French FS; Wilson EM
    Endocrinology; 1990 Dec; 127(6):3180-6. PubMed ID: 1701137
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New histopathological experimental model for benign prostatic hyperplasia: stromal hyperplasia in rats.
    Mori F; Oda N; Sakuragi M; Sakakibara F; Kiniwa M; Miyoshi K
    J Urol; 2009 Feb; 181(2):890-8. PubMed ID: 19095262
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Etiology of benign prostatic hyperplasia.
    Lee C; Kozlowski JM; Grayhack JT
    Urol Clin North Am; 1995 May; 22(2):237-46. PubMed ID: 7539172
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Functional morphology of the prostate].
    Aumüller G
    Urologe A; 1989 Nov; 28(6):306-10. PubMed ID: 2481355
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Regulation of prostatic growth, pathogenesis of prostatic adenoma and cancer].
    Darenkov AF; Evdokimov VV; Alfimov AE
    Vestn Ross Akad Med Nauk; 1994; (11):50-9. PubMed ID: 7530531
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of growth factors in the pathogenesis of BPH.
    Habib FK
    Prog Clin Biol Res; 1994; 386():43-50. PubMed ID: 7528412
    [No Abstract]   [Full Text] [Related]  

  • 33. Platelet derived growth factor (PDGF), androgens and inflammation: possible etiologic factors in the development of prostatic hyperplasia.
    Gleason PE; Jones JA; Regan JS; Salvas DB; Eble JN; Lamph WW; Vlahos CJ; Huang WL; Falcone JF; Hirsch KS
    J Urol; 1993 Jun; 149(6):1586-92. PubMed ID: 7684794
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Growth factors and prostatic tumors].
    Cussenot O
    Ann Endocrinol (Paris); 1997; 58(5):370-80. PubMed ID: 9685995
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Benign prostatic hyperplasia: age-related tissue-remodeling.
    Untergasser G; Madersbacher S; Berger P
    Exp Gerontol; 2005 Mar; 40(3):121-8. PubMed ID: 15763388
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Insulin-like growth factor axis abnormalities in prostatic stromal cells from patients with benign prostatic hyperplasia.
    Cohen P; Peehl DM; Baker B; Liu F; Hintz RL; Rosenfeld RG
    J Clin Endocrinol Metab; 1994 Nov; 79(5):1410-5. PubMed ID: 7525636
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanisms of synergism between antagonists of growth hormone-releasing hormone and antagonists of luteinizing hormone-releasing hormone in shrinking experimental benign prostatic hyperplasia.
    Rick FG; Schally AV; Block NL; Abi-Chaker A; Krishan A; Szalontay L
    Prostate; 2013 Jun; 73(8):873-83. PubMed ID: 23280565
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Experimental research on spontaneous benign prostatic hyperplasia in old dogs].
    Cai RF; Cui YG; Hua LX; Jia Y; Ma DZ; Wang XH
    Zhonghua Nan Ke Xue; 2003 Dec; 9(9):651-3, 657. PubMed ID: 14727348
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A new mouse model for prostatic hyperplasia: induction of adult prostatic overgrowth by fetal urogenital sinus implants.
    Chung LW; Matsuura J; Rocco AK; Thompson TC; Miller GJ; Runner MN
    Prog Clin Biol Res; 1984; 145():291-306. PubMed ID: 6201880
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combining growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist greatly augments benign prostatic hyperplasia shrinkage.
    Rick FG; Szalontay L; Schally AV; Block NL; Nadji M; Szepeshazi K; Vidaurre I; Zarandi M; Kovacs M; Rekasi Z
    J Urol; 2012 Apr; 187(4):1498-504. PubMed ID: 22341819
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.